diphenylhexatriene and Zellweger-Syndrome

diphenylhexatriene has been researched along with Zellweger-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for diphenylhexatriene and Zellweger-Syndrome

ArticleYear
Influence of plasmalogen deficiency on membrane fluidity of human skin fibroblasts: a fluorescence anisotropy study.
    Biochimica et biophysica acta, 1989, Jan-16, Volume: 978, Issue:1

    The influence of plasmalogen deficiency on membrane lipid mobility was determined by measuring fluorescence anisotropy of trimethylammoniumdiphenylhexatriene (TMA-DPH) and diphenylhexatrienylpropanoylhydrazylstachyose (glyco-DPH) inserted in the plasma membranes of human skin fibroblasts deficient in plasmalogens. The cells used were from patients affected with cerebrohepatorenal (Zellweger) syndrome (CHRS) or rhizomelic chondrodysplasia punctata. Their plasmalogen content (0-5% of total phospholipid) is significantly reduced compared with that of control cells from healthy donors (13-15% of total phospholipid) or of CHRS fibroblasts supplemented with the plasmalogen precursor, hexadecylglycerol. Plasmalogen-deficient cells consistently showed lower fluorescence anisotropies of membrane-bound DPH fluorophores corresponding to higher membrane lipid mobilities as compared to controls. However, very similar lipid mobilities were found for sonicated aqueous dispersions of phospholipids extracted either from CHRS or control cells. Therefore, the differences observed with living cells are not due to differences in the overall physical properties of the membrane lipid constituents. Other phenomena such as lipid asymmetry and/or plasmalogen-protein interactions may be responsible for the effects observed in the biomembranes.

    Topics: Cell Membrane; Chondrodysplasia Punctata; Diphenylhexatriene; Fibroblasts; Fluorescence Polarization; Fluorescent Dyes; Humans; Membrane Fluidity; Membrane Lipids; Oligopeptides; Plasmalogens; Zellweger Syndrome

1989